![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » Insmed Begins Trial With SomatoKine in Type A Extreme Insulin Resistance
Insmed Begins Trial With SomatoKine in Type A Extreme Insulin Resistance
Insmed has initiated a Phase II clinical trial examining the therapeutic benefit of treating Type A Extreme Insulin Resistance with SomatoKine, the company's proprietary once daily IGF-I therapy.
The clinical trial is a Phase II, open-label, dose-ranging study designed to evaluate the safety and efficacy of SomatoKine for 16 weeks in 10 patients with Type A Extreme Insulin Resistance. To qualify for inclusion in the study, patients must be between 10 and 65 years of age and have a diagnosis of Type A insulin resistance.
The primary efficacy endpoints of the trial are improvement in glycemic control, improvement in insulin sensitivity, reduction in hemoglobin A1c and improvement in body composition.
KEYWORDS Drug Pipeline Alert
Upcoming Events
-
21Oct